Ovid Therapeutics (OVID) Accumulated Expenses (2016 - 2026)

Ovid Therapeutics (OVID) has reported Accumulated Expenses for 11 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 54.04% year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (up 54.04% YoY), and the FY2025 full-year result was $4.9 million, down 18.27% from the prior year.
• Accumulated Expenses retreated to $4.4 million in Q2 2026 per OVID's latest filing, from $5.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.1 million in Q2 2024 and bottomed at $2.9 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $5.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses plunged 64.58% in 2025, then jumped 54.04% in 2026.
• Over 5 years, Accumulated Expenses stood at $4.5 million in 2022, then soared by 44.83% to $6.5 million in 2023, then slipped by 8.12% to $6.0 million in 2024, then declined by 18.27% to $4.9 million in 2025, then retreated by 9.7% to $4.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $4.4 million, $5.4 million, and $4.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.